Dendritic cells are antigen-presenting cells of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems. Dendritic cells are present in those tissues that are in contact with the external environment, such as the skin and the inner lining of the nose, lungs, stomach and intestines. They can also be found in an immature state in the blood. Once activated, they migrate to the lymph nodes where they interact with T cells and B cells to initiate and shape the adaptive immune response.
Anthony Harrelson is the founder and CEO of White Oak Industries, a biopharmaceutical company working to develop immunotherapeutic treatments for some of the world’s most contagious and deadliest infectious diseases, including Ebola and HIV. White Oak Industries has devoted a large amount of research to develop a vaccine for clade B HIV-1, a strain of the virus that affects millions of people worldwide. White Oak Industries has discovered the role of dendritic cells in the immune system and developed a method to generate dendritic cells triggering a response in the cells of a human creating a seek and destroy cell preventing the cells of a virus in this case HIV from hiding giving our treatment the opportunity to completely destroy any virus that would be hiding in any tissue in the human body.
Anthony Harrelson says that a critical part of the development of HIV and Ebola immunotherapy treatment programs at his company is already partnering with some Nongovernmental Organizations and universities to strengthen the organization and their important work. With the help of his development team and a collaborative effort from the medical community and NGO community, Harrelson says that his treatments will reach those who need them in the developing world within the next few years if all goes according to plan. The important research they do on the dendritic cells will help to develop the advancements in antiviral treatments.
Anthony Harrelson is the founder and CEO of White Oak Industries, a biopharmaceutical company working to develop immunotherapeutic treatments for some of the world’s most contagious and deadliest infectious diseases, including Ebola and HIV. White Oak Industries has devoted a large amount of research to develop a vaccine for clade B HIV-1, a strain of the virus that affects millions of people worldwide. White Oak Industries has discovered the role of dendritic cells in the immune system and developed a method to generate dendritic cells triggering a response in the cells of a human creating a seek and destroy cell preventing the cells of a virus in this case HIV from hiding giving our treatment the opportunity to completely destroy any virus that would be hiding in any tissue in the human body.
Anthony Harrelson says that a critical part of the development of HIV and Ebola immunotherapy treatment programs at his company is already partnering with some Nongovernmental Organizations and universities to strengthen the organization and their important work. With the help of his development team and a collaborative effort from the medical community and NGO community, Harrelson says that his treatments will reach those who need them in the developing world within the next few years if all goes according to plan. The important research they do on the dendritic cells will help to develop the advancements in antiviral treatments.